Please login to the form below

Not currently logged in
Email:
Password:

metformin

This page shows the latest metformin news and features for those working in and with pharma, biotech and healthcare.

Latest news

More from news
Approximately 6 fully matching, plus 183 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Complements are products that are often used together. Sometimes this distinction becomes blurred, as with metformin, which is a treatment for type II diabetes in its own right and also used ... market. The large product beside Januvia is metformin that,

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage. ... We probably have the broadest offering of products in diabetes in that middle space from when people start in

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

  • Rise of generic medicines in Portugal Rise of generic medicines in Portugal

    Generics bestsellers in volume. Simvastatin. Alprazolam. Oneprazol. Ibuprofen. Paracetamol. Metformin. Nimesulide.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    The most commonly used oral/ non-insulin injectables are Metformin (37 per cent), Glucobay (21 per cent), Glipizide (15 per cent) and Tangshiping (11 per cent). ... In March 2013, Merck Serono and Bristol-Myers Squibb struck a deal to co-promote a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics